



**Insulin Patient  
Advisory Council  
Quarterly Meeting**

---

January 27, 2026

# Virtual Meeting Etiquette



1

**Mute your microphone when you are not speaking to avoid background noise**



2

**Use of your camera is encouraged**



3

**Raise your virtual hand or use the chat feature for questions/comments**



# Agenda



- |   |         |
|---|---------|
| 1. Welcome  | 2:30 PM |
| 2. CalRx Insulin Glargine Pen Distribution & Communications Updates | 2:35 PM |
| 3. Targeted Outreach Discussion Questions                           | 3:15 PM |
| 4. 2026 Council Member Reappointment Process                        | 4:15 PM |
| 5. Next Steps & Adjournment   | 4:30 PM |

# Meeting Operating Principles



- Communicate clearly and concisely
- Ensure all participants who wish to speak, have the chance to do so
- Respectfully listen to the perspective of others
- Ask questions if clarification is needed
- Avoid jargon whenever possible
- Keep comments relevant to the issue being discussed


# CalRx<sup>®</sup> Insulin Glargine Pen Distribution & Communications Updates

# Prescriber & Patient Resources



CalRx® Insulin

Affordable for All Californians




CalRx® Insulin Glargine is now available  
at \$55 for a 5 pack of 3 mL pens<sup>1</sup>

CalRx brings Californians a U.S. Food and Drug Administration approved **affordable insulin** option. In partnership with **Civica**®, CalRx lowers the cost of insulin which helps more individuals get the medicine they need. CalRx® Insulin Glargine costs just \$55 for a 5-pack of 3 mL pens without insurance. Your price with insurance may be lower. Ask your insurance what's covered and how much it costs.

**What is CalRx® Insulin Glargine?**


**CalRx® Insulin Glargine-yfgn** is a long-acting insulin used to treat diabetes. It contains the same active ingredient and works just like Lantus®. Pharmacists can substitute CalRx® for Lantus® at the pharmacy counter using your existing insulin prescription.

Ask your healthcare provider or pharmacist about switching to  
CalRx® Insulin Glargine today!



Scan the QR code or visit [Civicalnsulin.org](https://civicalnsulin.org)


Get more information by asking your healthcare provider or visiting the CalRx website at <https://calrx.ca.gov/biosimilar-insulin-initiative/>



Patient Flyer

CIVICA®

CIVICA SCRIPT®



New low-cost Civica insulin  
glargine-yfgn now available

The new low-cost insulin glargine-yfgn is **interchangeable for the reference brand, Lantus®**<sup>1</sup> (insulin glargine), allowing substitution at the pharmacy counter.<sup>2</sup>

**WHOLESALE PER BOX \$45**

**MAX RECOMMENDED CONSUMER COST \$55**

The new insulin glargine-yfgn is available in pre-filled pens. It is available to wholesalers for \$45 for a box of five pen cartridges. We have set a maximum recommended price to the consumer of no more than \$55/box.

Insulin glargine-yfgn is manufactured by Biocon Biologics. It has a Civica label and is marketed nationally by CivicaScript. In California, it carries a CalRx® brand as part of our partnership with the state. Specific information about the use of insulin glargine-yfgn can be found [here](#).

Civica-branded NDC: 72572-422-05


CalRx-branded NDC: 72572-424-05

Preferred on these formularies	Anthem Blue Cross of California Commercial	Blue Shield of California Commercial	Federal Employees Plan Commercial
Available via these wholesalers	Cardinal Health <a href="http://cardinalhealth.com">cardinalhealth.com</a>	Cencora <a href="http://cencora.com">cencora.com</a>	McKesson <a href="http://mckesson.com">mckesson.com</a>
Questions?	Contact us at <a href="mailto:InsulinQuestions@civicarx.org">InsulinQuestions@civicarx.org</a>		

Pharmacy Fact Sheet

CalRx® Insulin Glargine

Frequently Asked Questions (FAQs)



**What is CalRx® Insulin Glargine and why is it different?**

CalRx® Insulin Glargine is a low-cost, biosimilar, long-acting insulin produced under a California state initiative to make essential drugs more affordable. CalRx® Insulin Glargine is designated interchangeable, meaning that it is the same as the reference product, Lantus®. Your pharmacist can substitute it for eligible long-acting insulin products without requiring a new prescription.

**How do I switch to CalRx® Insulin Glargine from another insulin?**

Many patients can switch from other long-acting insulin products without needing a new prescription. Your pharmacist can confirm eligibility. Switching should only be done under supervision and monitoring by your healthcare provider to prevent issues with blood sugar control.

**Do I need a new prescription?**

No. CalRx® Insulin Glargine is designated interchangeable, meaning that it is the same as the reference product, Lantus®. Your pharmacist can substitute it for eligible long-acting insulin products without requiring a new prescription.

**Will it work the same as Lantus®?**

Yes. It's held to the same FDA standards and has been shown in rigorous testing to be just as effective and safe.


**What will CalRx® Insulin Glargine cost?**

The maximum retail price for CalRx® Insulin Glargine is \$55 for a 5-pack of 3 mL pens, although your costs may be lower if purchasing through insurance.

**Can I purchase a single CalRx® Insulin Glargine pen for \$11?**

No. CalRx® Insulin Glargine can only be purchased as a 5-pack of 3 mL pens at the maximum retail price of \$55, an average cost of \$11 per pen.

FAQs



Department of Health Care  
Access and Information

6

# CalRx® Insulin Communications Update



- HCAI presented at Covered California's 12/3/25 carrier call and the California Department of Public Health's 1/14/26 Local Health Department leadership call
- HCAI & Civica disseminated a Pharmacy Fact Sheet and [CalRx pharmacy survey](#) through the California Pharmacists Association & California Council of Pharmacy Deans to identify independent pharmacies that plan to carry CalRx® insulin
- HCAI provided a social media toolkit to this Council & other diabetes patient advocacy groups to help amplify our messaging
- HCAI is in process of translating its [patient resources](#) in the top 5 Medi-Cal threshold languages (Spanish, Chinese, Tagalog, Vietnamese, and Korean)
- HCAI is also disseminating materials through CA legislators in newsletters to constituents


# CalRx<sup>®</sup> Insulin Distribution Update

This map overlays initial data on independent pharmacy locations that plan to carry CalRx<sup>®</sup> insulin among diabetes prevalence rates by region. As a new product, broad distribution to all parts of the state will take time due to decisions by health plans on formulary coverage and pharmacies on whether to stock.

The darkest orange regions represent diabetes prevalence greater than 20%. The geographic areas with higher diabetes prevalence and lower pharmacy access are **San Joaquin Valley, Rural Inland Northern CA, and sections of Los Angeles County.**

Region	Diabetes Prevalence
Southern San Joaquin Valley	11.90%
Northern San Joaquin Valley	11.39%
Los Angeles	11.37%
Inland Empire	10.72%
San Francisco Bay Area	10.04%
Superior California	10.02%
Orange	9.92%
San Diego - Imperial	9.82%
Central Coast	9.65%
North Coast	9.24%

Sources: CalRx pharmacy survey data as of 1/23/26 and 2023 aggregated diabetes prevalence data from the Healthcare Payments Data Program’s medical and pharmacy claims, inpatient stays, emergency department visits, and mortalities




# CalRx<sup>®</sup> Insulin Distribution Update: Los Angeles

As California's most populous county, diabetes prevalence varies within sections of Los Angeles.

The weighted diabetes prevalence in Los Angeles is 11.36%; however, at the zip code level, prevalence ranges from approximately 0.0% to 34.3%.

When examined at the zip code level, diabetes prevalence is greatest in **San Fernando Valley and San Gabriel Valley**.

We appreciate your support and ideas for increasing awareness of CalRx<sup>®</sup> insulin among these priority communities.





# Questions



# Media List: Council Feedback

# Targeted Outreach Discussion Questions

# 2026 Council Member Reappointment Process

# 2026 Council Member Reappointment Process



- HCAI will request an updated Appointment Acceptance Form from all Council members for the new term year (April 2026 – March 2027).
- Please complete & return or notify HCAI if you are no longer interested in serving on the Council by **Friday, February 13.**
- If there are vacancies, HCAI will disseminate the Submission of Interest survey to past applicants. Any vacancies will be filled before the next Council meeting.
- Thank you for considering to continue serving on this Council!



# Questions

# 2025-26 Year in Review

April

- Council kickoff & orientation
- Insulin market discussion questions

July

- Overview of biosimilar drug development process by Civica
- Insulin market analysis presentation by HCAI
- Mail order vs. community pharmacy discussion questions

November

- January 2026 white label insulin glargine pen launch
- Patient & prescriber communications planning
- Presentation of 2024 out-of-pocket expenses & rationing survey results by T1I

January

- CalRx<sup>®</sup> insulin glargine pen distribution update
- Targeted outreach discussion questions
- Council member reappointment process

# Next Meeting

April  
2026

- Insulin distance dashboard presentation by HCAI



# Thank you.

**Next Council Meeting:  
Tuesday, April 28, 2026  
2:30 – 4:30 p.m. (PST)**